Glenmark Pharmaceuticals will remain in focus as the French pharma major Sanofi filed a patent infringement petition against Glenmark for the cardiac drug Multaq, in the district court of Delaware, US. Sanofi and Sanofi-Aventis US LLC filed the suit against Glenmark and Actavis (Watson) on February 26 seeking to prevent the duo from commercialising its product prior to the expiration of certain US patents. Glenamark had filed its application with US FDA for its drug on January 24.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.